If you have been reading about hGH fragment and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
With the exception of biopharmaceuticals, which are manufactured by only a few selected fine chemical companies, the technology toolboxes of all these companies are similar. This means that they can carry out practically all types of chemical reactions. They differentiate on the basis of the breadth and quality of the service offering.
== History == Myelofibrosis was first described in 1879 by Gustav Heuck. Eponyms for the disease are Heuck-Assmann disease or Assmann's Disease, for Herbert Assmann, who published a description under the term "osteosclerosis" in 1907. It was characterised as a myeloproliferative condition in 1951 by William Dameshek. The disease was also known as myelofibrosis with myeloid metaplasia and agnogenic myeloid metaplasia The World Health Organization utilized the name chronic idiopathic myelofibrosis until 2008, when it adopted the name of primary myelofibrosis. In 2016, the WHO revised their classification of myeloproliferative neoplasms to define Prefibrotic primary myelofibrosis as a distinct clinical entity from overt PMF.
=== Hearing loss === Alport syndrome can also cause hearing loss although some patients are not affected. Hearing in Alport syndrome patients is normal at birth. Hearing loss in affected patients develops progressively, usually at the stage when kidney function is normal, but there is substantial proteinuria. However, in some patients, hearing loss is only noted after kidney function has been lost. Characteristically the early changes are reduced ability to hear high-frequency sounds, sensorineural deafness. This becomes more severe and affects lower frequencies too. Hearing loss is not usually complete in Alport syndrome; good communication is almost always possible with the use of hearing aids.
Afterwards, Larter commented on future producing endeavors during an interview about Resident Evil: Extinction: "I definitely have many ideas and different avenues that I want to take as my career goes on." In 2005, she appeared in Confess, an independent political thriller, and had a role in the romantic comedy A Lot Like Love, starring Amanda Peet and Ashton Kutcher. Also in 2005, she returned to living in Los Angeles.
Sources: en.wikipedia.org
On 26 September, Trump rejected Iran's seven-day ceasefire proposal and expressed doubt that Tehran would eventually comply with his administration's nuclear demands. In a phone interview the following day, Trump said that he still expected more talks with Iran to resume during the week. Trump claimed that Iran "wanted to make a deal," but they "overplayed their hand" by offering conditions that the US "would have maybe agreed to a year ago." By late September 2026, crude oil and petroleum flows through the Strait of Hormuz had recovered to 77% to 80% of pre-war levels, totaling an estimated 13.19 million barrels per day. A US Navy campaign that used armed convoy escorts and unmonitored "dark transits" was responsible for the stabilization of shipping traffic. Iran's own oil and petrochemical exports were severely limited at the same time due to the combined effects of an active US naval blockade and a broad secondary sanctions campaign known as Operation Economic Outcast. This economic contraction drove the Iranian rial to a historic low of 2.5 million rials per U.S. dollar, significantly eroding Iran's primary geopolitical leverage against Washington. Despite the decline in its conventional enforcement capabilities, the IRGC maintained asymmetric tactics, ensuring maritime insurance premiums remained highly elevated. As worries about Iranian retaliation grew, the US military sent two more Patriot missile batteries to Saudi Arabia and Qatar in September 2026 to safeguard vital energy infrastructure.
Beeby, K.J. The Wonderful Story of Leather (PDF). UK: Harmatan. Archived (PDF) from the original on 20 March 2021. Retrieved 8 June 2016. Lefroy, George Alfred (1884). The leather-workers of Daryaganj . Delhi: Cambridge Mission to Delhi. Leathers for Bookbinding and Upholstery (PDF). UK: Harmatan. 2002. Archived (PDF) from the original on 20 March 2021. Retrieved 8 June 2016. Leather for Libraries (PDF). UK: Harmatan. Archived (PDF) from the original on 20 March 2021. Retrieved 8 June 2016. Parsons, F. G. (1911). "Leather" . Encyclopædia Britannica. Vol. 16 (11th ed.). pp. 330–345. (includes several diagrams)
== Hydration states == Calcium sulfate occurs at three levels of hydration with different crystallographic structures: anhydrous, dihydrate, and hemihydrate. The anhydrous CaSO4 (anhydrite) crystallizes as an tightly-bound orthorhombic lattice with space group Pnma, in which each Ca2+ is 8-coordinated, or surrounded, by 8 oxygen atoms from tetrahedral SO2−4. It is similar in topology to zircon. The dihydrate CaSO4·2H2O (gypsum) forms a monoclinic crystal with space group C2/c. Its structure consists of alternating layers: one with Ca2+ coordinated with tetrahedral SO2−4 and another with interstitial water molecules. The hemihydrate CaSO4·1/2H2O (bassanite) is also known as plaster of Paris. Specific hemihydrates are sometimes distinguished between α-hemihydrate and β-hemihydrate.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.